Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | VNN1 | O95497 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18032452 | 0.83 | VNN1 (0.42) | VNN1KDM5A | |
| SCHEMBL17722618 | 0.81 | PDCD1LG2 (0.41) | PDCD1LG2CD274EPHX2DRD2DRD3 | |
| SCHEMBL24711532 | 0.81 | PDCD1LG2 (0.41) | PDCD1LG2CD274EPHX2DRD2DRD3 | |
| SCHEMBL21739463 | 0.81 | PDCD1LG2 (0.41) | PDCD1LG2CD274EPHX2DRD2DRD3 | |
| SCHEMBL25664016 | 0.77 | PIK3CD (0.44) | PDCD1LG2CD274EPHX2DRD2KDM5A | |
| SCHEMBL18849760 | 0.75 | PDCD1LG2 (0.32) | PDCD1LG2CD274VNN1 | |
| SCHEMBL12563401 | 0.75 | PDCD1LG2 (0.32) | PDCD1LG2CD274VNN1 | |
| SCHEMBL18849759 | 0.75 | PDCD1LG2 (0.32) | PDCD1LG2CD274VNN1 | |
| SCHEMBL18032445 | 0.74 | CTSS (0.39) | VNN1KDM5A | |
| SCHEMBL25666931 | 0.74 | PDCD1LG2 (0.38) | PDCD1LG2CD274EPHX2DRD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | SLCO1A2, SLCO2B1, SLCO2A1 | PDCD1LG2 4761/4885CD274 4844/4885EPHX2 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.